Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analysts’ consensus is “Moderate Buy”: Four of five covering brokerages rate Rani Therapeutics a buy, while one recommends selling; the average 12-month price target is $8.33.
• Quarterly results beat estimates: Rani reported a loss of $0.04 per share versus the expected $0.05 loss, and revenue of $1.71 million versus the $1.28 million consensus.
• The stock remains near its 52-week low: Shares opened at $0.57, compared with a 52-week range of $0.51 to $2.15. AWM Investment Company disclosed a new position of 7.5 million shares, or about 6.05% of the company.

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus rating of "Moderate Buy" from the five brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $8.33.

A number of brokerages recently commented on RANI. Weiss Ratings raised shares of Rani Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 30th. HC Wainwright reissued a "buy" rating on shares of Rani Therapeutics in a research note on Tuesday, October 6th. Finally, Chardan Capital reissued a "buy" rating on shares of Rani Therapeutics in a research note on Thursday, October 22nd.

Rani Therapeutics Stock Up 1.4%

RANI stock opened at $0.57 on Thursday. Rani Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.15. The firm has a market capitalization of $79.18 million, a P/E ratio of -2.99 and a beta of 0.61. The company has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $0.90.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.71 million for the quarter, compared to the consensus estimate of $1.28 million. Rani Therapeutics had a negative net margin of 493.00% and a negative return on equity of 76.64%. As a group, analysts anticipate that Rani Therapeutics will post -0.17 EPS for the current year.

Hedge Funds Weigh In On Rani Therapeutics

A hedge fund recently bought a new position in Rani Therapeutics stock. AWM Investment Company Inc. purchased a new position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,500,000 shares of the company's stock, valued at approximately $5,703,000. AWM Investment Company Inc. owned about 6.05% of Rani Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 30.19% of the company's stock.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion. The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.